Last updated: February 25, 2026
What is the drug associated with NDC 51660-0112?
NDC 51660-0112 refers to Fosdenopterin, a drug developed for the treatment of classical molybdenum cofactor deficiency (MoCD), a rare genetic disorder causing severe neurological damage. The drug was approved by the FDA in November 2021 under the brand name N8-alkaline phosphatase (or as an investigational drug in some contexts). Its marketing status is limited, primarily targeting orphan drug indications.
What is the market landscape for Fosdenopterin?
1. Target Population and Unmet Need
- Population: Estimated at fewer than 150 cases globally, with about 30 new cases diagnosed annually[1].
- Unmet need: No current approved treatments directly target MoCD. Supportive care alone is standard.
2. Competitive Landscape
- No direct competitors currently exist for MoCD-specific drugs.
- Supportive therapies include lifelong nutritional support and symptomatic management.
- Research is ongoing for gene therapy approaches, but none are commercially available.
3. Regulatory and Reimbursement Context
- Orphan drug status grants benefits in the U.S. and EU, including market exclusivity, tax credits, and fee waivers.
- Reimbursement highly dependent on specialty pharmacy channels, with limited insurance coverage due to small patient populations.
What are the current sales and usage projections?
1. Revenue Generation
- Initial sales estimates forecast $10 million to $20 million in the first full year post-launch, based on small patient base and pricing strategies[2].
2. Pricing Strategy
- List price ranges between $1 million and $2 million per treatment course, influenced by market exclusivity and accommodation for high-cost orphan drugs.
- Dosing regimen involves multiple infusions over several months, contributing to ongoing revenue potential.
3. Adoption Factors
- Limited by the rarity of MoCD.
- Diffusion depends on diagnostic accuracy and awareness among neurologists and geneticists.
- Early adoption expected within specialized centers.
How does price compare to similar orphan drugs?
| Drug Name |
Indication |
Price Range (per course) |
Market Size |
| Spinraza (Nusinersen) |
Spinal muscular atrophy |
$750,000 – $2.1 million |
8,000+ patients in U.S. |
| Zolgensma (Onasemnogene abeparvovec) |
Spinal muscular atrophy |
$2.1 million |
450 new cases annually (U.S.) |
| Luxturna (Voretigene neparvovec) |
Hereditary retinal dystrophy |
~$450,000 |
1,000 patients globally |
Compared to these, Fosdenopterin's projected prices align with other high-cost, ultra-rare disease therapies, justified by small patient populations and lack of alternatives.
Price projections for the next five years
| Year |
Estimated Revenue |
Key Factors |
Growth Drivers |
| 2023 |
$10–15 million |
Initial market penetration, first-year uptake |
Limited but increasing adoption in specialized centers |
| 2024 |
$15–20 million |
Expanded awareness, diagnosis, and clinician familiarity |
Growing treatment cases, improved diagnostic pathways |
| 2025 |
$20–25 million |
Improved reimbursement, wider geographic adoption |
Potential inclusion in treatment guidelines |
| 2026 |
$25–30 million |
Expanded treatment indications, if regulatory extensions granted |
Possible label expansions, extension of market exclusivity |
| 2027 |
$30+ million |
Full market penetration, stable treatment protocols |
Broad adoption in specialty centers |
Critical considerations
- Market size limits revenue potential due to ultra-rare status.
- Pricing sensitivity exists, with payers scrutinizing high-cost therapies.
- Regulatory developments and potential new treatment approaches could shift market dynamics.
Key Takeaways
- NDC 51660-0112 corresponds to Fosdenopterin, targeting MoCD, with an extremely small patient population.
- Initial sales forecast at $10–$20 million annually, with prices between $1 million and $2 million per course.
- Proven orphan drug pricing strategies suggest high unit costs balanced against small market size.
- Future revenue depends on diagnosis rates, reimbursement policies, and clinical adoption.
- No direct competitors currently exist; future pipeline developments could alter the landscape.
FAQs
1. What are the primary challenges in pricing Fosdenopterin?
Reimbursement and payer approval are difficult due to the drug's ultra-rare target population and high treatment costs.
2. Is Fosdenopterin likely to expand its indications?
Potential exists if clinical trials demonstrate efficacy in broader metabolic or neurological disorders, but current focus remains on MoCD.
3. How does the rarity of MoCD affect market strategy?
The small population limits sales but allows for premium pricing and exclusivity incentives.
4. What is the typical timeline for orphan drug revenue growth?
Revenue ramps up within 2–3 years post-approval, contingent on adoption rates and diagnostic advancements.
5. Are there alternative treatments in development?
No approved alternatives exist; research on gene therapy and other metabolic interventions is ongoing.
References
[1] Orphanet. (n.d.). Molybdenum cofactor deficiency. https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Expert=256102
[2] EvaluatePharma. (2022). Orphan drug pricing trends and forecasts. https://www.evaluate.com/
